Benzodiazepine Discontinuation Guidelines for Older Adults
1. Risks of Using Diazepam in the Elderly
- Long‑acting benzodiazepines such as diazepam are classified as high‑risk medications for patients aged ≥ 65 years by the Beers Criteria and should be avoided because they increase sedation, cognitive impairment, unsafe mobility (fall risk), motor‑skill deficits, and drug accumulation due to a prolonged half‑life. 1
- Switching a 75‑year‑old patient from lorazepam to diazepam to facilitate discontinuation is generally not recommended and may raise the likelihood of adverse events in this age group. 1
2. Preferred Tapering Approach
- The recommended strategy is a direct lorazepam taper without introducing another benzodiazepine. This is endorsed by both CDC’s MMWR recommendations and Mayo Clinic guidelines. [2][3]
- A gradual dose reduction of approximately 25 % every 1–2 weeks is commonly used and considered safe; however, in older adults the taper should often be slower to accommodate reduced tolerance. 2
- For patients with ≥ 1 year of continuous benzodiazepine use, a 10 % reduction per month or slower yields better tolerability than more rapid tapers. 4
3. Safety Considerations During Taper
- Abrupt discontinuation must be avoided because it can precipitate serious withdrawal complications, including rebound anxiety, hallucinations, seizures, delirium tremens, and, in rare cases, death. 2
- Close monitoring for withdrawal symptoms (e.g., anxiety, insomnia, tremor, autonomic instability) is essential; if symptoms become clinically significant, the taper rate should be further slowed. [2][4]
- Rapid tapers increase the risk of seizures and severe withdrawal; therefore, taper speed must be individualized and conservative. [2][4]
4. Adjunctive Strategies to Support Discontinuation
- Cognitive‑behavioral therapy (CBT) markedly improves taper success and should be offered alongside the medication reduction plan. [2][3]
- The EMPOWER trial demonstrated that patient education combined with a gradual taper achieved a 27 % discontinuation rate versus 5 % in usual‑care controls, providing high‑quality evidence for an educational‑behavioral approach. [3][5]
- Alternative non‑benzodiazepine treatments for anxiety and insomnia—such as SSRIs/SNRIs, CBT, sleep‑hygiene measures, and relaxation techniques—are recommended, while avoiding substitution with other potentially hazardous medications. [2][3]5
5. Common Pitfalls to Avoid
- Do not use diazepam as a “tapering agent” in elderly patients; this contradicts geriatric prescribing guidelines. 1
- Do not abandon the patient if tapering proves difficult; schedule regular follow‑up visits (at least monthly) to provide ongoing support. 4
- Do not restart the previous dose without reassessment when withdrawal symptoms emerge; instead, pause or slow the taper. 4
6. Monitoring and Follow‑Up
- Monthly follow‑up visits are the minimum requirement during a taper, with more frequent contacts if withdrawal symptoms appear. Multidisciplinary team members (nurses, pharmacists) can deliver additional support via telephone or telehealth. 4
- The overall taper duration may extend from several months to over a year for older adults with long‑term benzodiazepine use; this extended timeline should be discussed with the patient at the outset. 4
Evidence‑Based Benzodiazepine Deprescribing Guidelines
Tapering Strategies
- Adults < 65 years with < 1 year of benzodiazepine use should have the dose reduced by ≈ 25 % every 1–2 weeks (direct taper without switching agents) as recommended by the Mayo Clinic guideline; evidence is low‑to‑moderate quality. 6
- Older adults (≥ 65 years) or patients with ≥ 1 year of continuous use should be tapered more slowly, at about 10 % reduction per month, to improve tolerability and limit withdrawal; this recommendation follows the Mayo Clinic guidance. 6
Non‑Pharmacological Adjuncts
- Combining patient education with a gradual taper yields a 27 % discontinuation rate versus 5 % with usual care (EMPOWER trial); this provides high‑quality evidence for the education‑plus‑taper approach. 6
- Offering alternative, non‑benzodiazepine treatments for anxiety and insomnia—such as SSRIs/SNRIs, sleep‑hygiene measures, relaxation techniques, and behavioral interventions—should accompany deprescribing (Mayo Clinic recommendation). 6
Risks and High‑Risk Medications in Older Adults
- Long‑acting benzodiazepines (e.g., diazepam) are classified as high‑risk medications for patients ≥ 65 years by multiple geriatric prescribing criteria, reflecting increased sedation, cognitive impairment, fall risk, and drug accumulation. 6
- High‑potency, long‑acting, or prolonged benzodiazepine use is deemed high‑risk in older adults according to geriatric prescribing criteria (Mayo Clinic). 6
- In older populations, benzodiazepine use is associated with cognitive impairment, reduced mobility, unsafe driving, functional decline, falls, fractures, and addiction (Mayo Clinic). 6
Guideline Recommendations on Indications
- Consensus guidelines advise that benzodiazepines be prescribed only for short‑term use (typically < 4 weeks); longer durations should trigger deprescribing considerations. 6
Evidence Quality and Strength (Beers Criteria)
- The 2023 Beers Criteria support 71.5 % of their benzodiazepine recommendations with moderate‑quality evidence and 21.1 % with high‑quality evidence (British Journal of Pharmacology). 7
Risks and Management of Benzodiazepine Tapering
Risks of Abrupt Discontinuation
Monitoring and Assessment During Taper
Patient‑Centric Support Strategies
Pharmacologic Alternatives and Adjuncts for High‑Risk Patients
Management of Concurrent Opioid Use and Other Comorbidities
Deprescribing Benzodiazepines in Advanced Alzheimer’s Disease
When Benzodiazepine Discontinuation Is Contraindicated
- Benzodiazepines should be maintained in patients who exhibit clinically significant psychotic symptoms, agitation, or aggression until these behaviors are stabilized, unless there is clear evidence that the benzodiazepine is worsening the symptoms. 12
When Deprescribing Is Recommended
- In individuals with severe or end‑stage dementia—characterized by dependence in most basic activities of daily living, inability to respond to the environment, or limited life expectancy—benzodiazepine deprescribing should be strongly considered as part of overall medication optimization. 13
Multidisciplinary Support and Documentation in Benzodiazepine Tapering
Role of the Pharmacist and Multidisciplinary Team
- Involving pharmacists and other clinicians in the tapering plan helps optimize medication management and provides additional patient support throughout the discontinuation process. 14
- Pharmacists can perform dose‑calculations, monitor for drug‑drug interactions, and deliver structured patient education to improve safety and adherence during the taper. 14
Documentation Practices
- Clinicians should document the clinical rationale for benzodiazepine discontinuation, the agreed‑upon taper schedule, the education provided to the patient, and any reasons for adjustments to the taper. 14
- Thorough documentation protects against liability concerns and ensures continuity of care across the multidisciplinary team. 14